Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

221.75 +1.79 (+0.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 147,525
Open 222.93
Bid (Size) 220.30 (10)
Ask (Size) 228.60 (1)
Prev. Close 219.96
Today's Range 220.70 - 223.76
52wk Range 118.18 - 280.62
Shares Outstanding 1,211,067,023
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
From BeiGene
Via Business Wire
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts... 
Via Benzinga

Performance

YTD
-2.15%
-2.15%
1 Month
+2.65%
+2.65%
3 Month
+1.09%
+1.09%
6 Month
+55.69%
+55.69%
1 Year
+6.85%
+6.85%

More News

Read More
BeiGene Earnings Perspective: Return On Capital Employed
Via Benzinga
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
4 Analysts Have This to Say About BeiGene
Via Benzinga
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
Via Benzinga
Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
Via Benzinga
Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Via Talk Markets
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
From BeiGene
Via Business Wire
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
From BeiGene
Via Business Wire
Five Best And Worst Performing Healthcare Stocks In January 2023
Via Talk Markets
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
From BeiGene
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
Via The Motley Fool
Five Best And Worst Performing Healthcare Stocks In December 2022
Via Talk Markets
Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
From BeiGene
Via Business Wire
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
From BeiGene
Via Business Wire
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
From BeiGene
Via Business Wire
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
From BeiGene
Via Business Wire
These Were The Five Best And Worst Performing Large-Cap Stocks In Q4 2022
Via Talk Markets
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
From BeiGene
Via Business Wire
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.